N
VIGL

Nuveen’s Vigil Neuroscience VIGL Stock Holding History

Nuveen’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,840
Closed -$91.5K – 3420
2024
Q1 		$91.5K Hold
26,840
– – ﹤0.01% 3252
2023
Q4 		$90.7K Buy
26,840
+2,125
+9% +$10.9K ﹤0.01% 3291
2023
Q3 		$133K Hold
24,715
– – ﹤0.01% 3096
2023
Q2 		$232K Buy
+24,715
New +$234K ﹤0.01% 3058

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Nuveen's VIGL Position: Q2 2024 in Review

Nuveen sold out of Vigil Neuroscience (VIGL) in Q2 2024, closing a stake of 26,840 shares — an estimated $91.5K sold.

Nuveen first reported a position in VIGL in Q2 2023 and held it in 4 quarters. The position peaked at $232K in Q2 2023. 58 funds tracked by Wall St. Rank hold VIGL as of Q2 2024.

  • Nuveen reported no remaining Vigil Neuroscience position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 26,840 Vigil Neuroscience shares in Q2 2024, an estimated $91.5K.
  • Nuveen first reported a position in Vigil Neuroscience in Q2 2023 and held it in 4 quarters.
  • Nuveen's Vigil Neuroscience position peaked at $232K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.